An increasing number of individuals receiving psoriasis biologics achieve clear/nearly clear skin (disease control). Clinical trial data indicate that some maintain disease control with lower doses, especially those with higher serum drug concentrations. This indicates the potential of model-informed precision dosing, an advanced therapeutic drug-monitoring technique, to guide dose minimization. We developed, validated, and tested a precision-dosing dashboard. We applied a model-informed precision-dosing approach that leveraged Bayesian estimation to predict individual pharmacokinetic parameters for personalized dosing recommendations. A pharmacokinetic model of the exemplar biologic risankizumab derived from phases I-III psoriasis trial data (13,123 observations from 1899 patients) was externally validated using real-world data from the United Kingdom. The Bayesian model (posterior prediction: mean absolute error = 0.89 mg/l, mean percentage error = 19.55%, root mean square error = 1.24 mg/l, R